New review maps advances in coronary intravascular imaging and computational methods to support safer, personalized percutaneous coronary intervention for heart disease patients
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Oct-2026 15:17 ET (23-Oct-2026 19:17 GMT/UTC)
Coronary artery disease remains the top global cause of death, yet standard angiography cannot visualize dangerous artery plaque, creating gaps for guiding percutaneous coronary intervention. This narrative review synthesizes 10 years of human studies, clinical trials and consensus documents covering established and emerging intravascular imaging plus computational tools. Hybrid catheter systems have completed first‑in‑human testing, while artificial‑intelligence plaque analysis delivers diagnostic accuracy comparable to expert readers. These technologies enable combined anatomical, compositional and functional vessel assessment, though broad clinical roll‑out still requires standardized validation and streamlined workflow integration.
Finding a few tumor cells hidden among billions of blood cells is one of the biggest challenges in liquid biopsy. Circulating tumor cells (CTCs), which break away from primary tumors and enter the bloodstream, can provide important clues about cancer progression and treatment response. However, their extremely low abundance—often only one to ten cells among a billion blood cells—makes them difficult to isolate and accurately identify.
In a new study published in Biomedical Analysis, researchers from Taiyuan University of Technology and Shanxi Bethune Hospital developed a new strategy that combines a microfluidic chip with artificial intelligence to address this challenge. The platform first separates tumor cells from surrounding blood cells according to their physical differences, then uses deep learning to identify the enriched cells from ordinary microscope images. This approach provides a new route toward simpler, less label-dependent CTC analysis.